Management of Rhinovirus/Enterovirus-Associated ARDS
For rhinovirus/enterovirus-associated ARDS, apply standard ARDS management protocols with lung-protective ventilation (tidal volume 4-8 mL/kg predicted body weight, plateau pressure <30 cm H₂O), consider corticosteroids, and provide supportive care—there is no specific antiviral therapy available for these viruses. 1
Core Ventilatory Management
The foundation of treatment follows the 2024 American Thoracic Society guidelines for all ARDS regardless of etiology 1:
Mandatory Interventions
- Lung-protective ventilation with tidal volumes 4-8 mL/kg predicted body weight and plateau pressures ≤30 cm H₂O (strong recommendation) 1, 2
- Higher PEEP strategy for moderate-to-severe ARDS without prolonged recruitment maneuvers (conditional recommendation) 1
- Prone positioning >12 hours/day for severe ARDS (PaO₂/FiO₂ <100) (strong recommendation) 2
Avoid
- Prolonged lung recruitment maneuvers (strong recommendation against) 1
- High-frequency oscillatory ventilation (strong recommendation against) 2
Pharmacologic Therapy
Corticosteroids
Use systemic corticosteroids for rhinovirus/enterovirus ARDS (conditional recommendation, moderate certainty) 1. Case reports demonstrate successful outcomes with dexamethasone courses in EV-HRV ARDS 3, 4. The 2024 guideline now supports corticosteroid use across all ARDS etiologies, representing an important update from prior recommendations.
No Antiviral Options
Critically, no approved antiviral therapy exists for rhinovirus or enterovirus 5, 6. Treatment remains entirely supportive. One case report mentions high-dose intravenous vitamin C, but this lacks robust evidence and should not be considered standard therapy 6.
Special Considerations for Immunosuppressed Patients
If ARDS develops during immunosuppressive therapy (e.g., JAK inhibitors, methotrexate for rheumatoid arthritis):
- Temporarily withdraw immunosuppression during acute illness 3
- Reintroduce disease-modifying agents cautiously after clinical stabilization and radiographic improvement 3
- Distinguish viral ARDS from drug-induced pneumonitis or underlying autoimmune interstitial lung disease through multiplex PCR confirmation 3, 5
Non-Invasive Strategies
Before intubation, attempt:
- High-flow nasal oxygen with prolonged awake proning 3
- Intermittent non-invasive ventilation for worsening dyspnea episodes 3
- Conservative fluid strategy 3
These approaches may prevent intubation in select patients, as demonstrated in recent case reports 3, 7.
Rescue Therapies for Refractory Hypoxemia
For severe ARDS unresponsive to standard measures:
- VV-ECMO in selected patients (conditional recommendation, low certainty) 1
- Neuromuscular blockade for early severe ARDS (conditional recommendation, low certainty) 1
- Consider inhaled nitric oxide as rescue therapy, though evidence is limited 6
Diagnostic Confirmation
Use multiplex RT-PCR on nasopharyngeal and bronchial specimens to confirm rhinovirus/enterovirus and exclude bacterial/fungal coinfection 5. This molecular diagnosis:
- Minimizes invasive diagnostic procedures 5
- Enables early de-escalation of empiric antibiotics when cultures remain negative 3
- Distinguishes viral ARDS from other mimics (drug toxicity, autoimmune lung disease)
Clinical Pitfalls
Do not dismiss rhinovirus/enterovirus as trivial pathogens in adults—while typically causing common colds, they trigger ARDS through cytokine storm (IL-1, IL-6, IL-8) causing severe alveolar-capillary injury 6. Risk factors include:
- Female sex 6
- Immunosuppression (particularly JAK inhibitors, methotrexate) 3, 7
- Recent viral infections (e.g., post-COVID-19) 4
- Underlying lung disease (COPD, emphysema) 6
Mortality remains high despite appropriate management 6, emphasizing the need for early recognition and aggressive supportive care.